PriceTargets.com logo

Dermata Therapeutics - DRMA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 417.24%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.16 As of 11/20/2024 01:00 AM ET
▲ +0.08 (7.41%)

This chart shows the closing price for DRMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dermata Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DRMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DRMA

Analyst Price Target is $6.00
▲ +417.24% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Dermata Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 417.24% upside from the last price of $1.16.

This chart shows the closing price for DRMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Dermata Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/21/2024Maxim GroupLower TargetBuy ➝ Buy$10.00 ➝ $6.00
3/23/2023Maxim GroupLower TargetBuy$240.00 ➝ $60.00
12/6/2022Maxim GroupLower Target$960.00 ➝ $240.00
10/3/2022Brookline Capital ManagementReiterated RatingBuy
3/30/2022Maxim GroupLower Target$2,160.00 ➝ $960.00
9/21/2021Brookline Capital ManagementReiterated RatingBuy$3,360.00
9/21/2021Brookline Capital AcquisitionInitiated CoverageBuy$3,360.00
9/14/2021Maxim GroupInitiated CoverageBuy$2,160.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Dermata Therapeutics logo
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.16
Low: $1.07
High: $1.45

50 Day Range

MA: $1.46
Low: $1.08
High: $2.32

52 Week Range

Now: $1.16
Low: $1.05
High: $13.35

Volume

545,943 shs

Average Volume

780,158 shs

Market Capitalization

$2.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Dermata Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Dermata Therapeutics in the last twelve months: Maxim Group.
View the latest analyst ratings for DRMA.

What is the current price target for Dermata Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Dermata Therapeutics in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 417.2%. Maxim Group has the highest price target set, predicting DRMA will reach $6.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $6.00 for Dermata Therapeutics in the next year.
View the latest price targets for DRMA.

What is the current consensus analyst rating for Dermata Therapeutics?

Dermata Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DRMA will outperform the market and that investors should add to their positions of Dermata Therapeutics.
View the latest ratings for DRMA.

What other companies compete with Dermata Therapeutics?

Other companies that are similar to Dermata Therapeutics include Sonoma Pharmaceuticals, Vincerx Pharma, Aytu BioPharma, Ensysce Biosciences and Jaguar Health. Learn More about companies similar to Dermata Therapeutics.

How do I contact Dermata Therapeutics' investor relations team?

The company's listed phone number is 858-800-2543 and its investor relations email address is [email protected]. The official website for Dermata Therapeutics is www.dermatarx.com. Learn More about contacing Dermata Therapeutics investor relations.